Skip to content

Lenalidomide

Unknown authors
Oct 2026 · Reactions weekly · Vol 2131, pp. 110 - 110 · 0 citations

TL;DR

How reliance on blast morphology alone in this context could be misleading is illustrated and the importance of integrating flow cytometry with other laboratory modalities to classify such complex malignancies and guide subsequent therapy is highlighted, highlighting therapy-related leukaemogenesis in survivors of this malignancy.

View source

Similar papers

Review Open access Oct 2026

Daratumumab, Lenalidomide, and Dexamethasone Combination with Subsequent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Newly Diagnosed POEMS Syndrome: A Case Report and Literature Review

POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin changes) is an orphan multisystem plasma cell dyscrasia-associated disease. It is challenging to diagnose because not all of the five signs included in this acronym may be evident on initial presentation. The diagnosis of POEMS syndrome is ju...

S. V. Semochkin, V. Lunin, A. Grachev et al. · 0 citations
Nov 2026

First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.

A 69-year-old female with newly diagnosed MLNFGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma remains in complete remission at 17 months after pemigatinib initiation, with treatment-related toxicity being manageable through dose modifications and temporary interr...

C. Stafylidis, E. Variami, E. Lakiotaki et al. · 0 citations
Open access Sep 2026

A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma.

Acute lymphoblastic leukemia (ALL) following lenalidomide (LEN) therapy is rare. A 64-year-old man developed myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) six years after LEN maintenance therapy following autologous stem cell transplantation for multiple myeloma, followed by Philadelphia chromosome-negative...

Takayuki Nakamura, Fumihiko Mouri, Yoshimi Maehiro et al. · 0 citations
Open access Oct 2026

Therapeutic Challenges In Chronic Lymphocytic Leukemia: A Case Report With 17p Deletion

Background: Chronic lymphocytic leukemia (CLL) presents a very high clinical-biological heterogeneity, and the therapeutic choice depends on several parameters, primarily the evolutionary stage of the disease and the presence of molecular anomalies such as the 17p deletion. We report the case of a patient with CLL for...

K. Bouzenda, Rym Gourmat, A. Zidani et al. · 0 citations
Open access Oct 2026

Case Report: Fulminant aggressive NK-cell leukemia with hemophagocytic lymphohistiocytosis and multiple organ dysfunction successfully bridged to allogeneic hematopoietic stem cell transplantation

Aggressive natural killer-cell leukemia (ANKL) is an exceedingly rare and rapidly fatal malignancy of mature NK cells, frequently associated with Epstein-Barr virus (EBV), and its diagnosis is often complicated by hemophagocytic lymphohistiocytosis (HLH) that can obscure the underlying malignancy and delay therapy. We...

Shu-Tan Li, Chao Fang · 0 citations
Case report Open access Oct 2026

Prolonged, transplant-free remission with tagraxofusp in combination with venetoclax for transplant-ineligible blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy predominantly affecting older adults. While the CD123-directed agent tagraxofusp has improved outcomes, durable long-term survival is typically limited to patients eligible for transplant, leaving effective transplant-free...

Tia Cheunkarndee, C. Schumann, N. Pemmaraju et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.